中国血液流变学杂志
中國血液流變學雜誌
중국혈액류변학잡지
CHINESE JOURNAL OF HEMORHEOLOGY
2014年
4期
527-529,539
,共4页
张微%邹玺%胡玥%李烜%胡守友%王瑞平
張微%鄒璽%鬍玥%李烜%鬍守友%王瑞平
장미%추새%호모%리훤%호수우%왕서평
甘露聚糖肽%化疗药物%恶性浆膜腔积液%治疗
甘露聚糖肽%化療藥物%噁性漿膜腔積液%治療
감로취당태%화료약물%악성장막강적액%치료
mannatide%cytotoxic drug%malignant effusion%therapy
目的:评价甘露聚糖肽联合化疗药物(顺铂和氟尿嘧啶)灌注治疗恶性浆膜腔积液的临床疗效及毒副反应。方法44例恶性浆膜腔积液患者随机分为2组,所有患者均经浆膜腔穿刺置管,充分引流积液后行灌注治疗,治疗组(n=23),灌注甘露聚糖肽40~50 mg,顺铂40~60 mg或者氟尿嘧啶0.5~1.0 g;对照组(n=21),灌注顺铂40~60 mg或者氟尿嘧啶0.5~1.0 g。48 h后开放引流管,保持引流通畅,每周1次,连用2周。结果治疗组有效率(RR)和疾病控制率(DCR)分别为47.8%(11/23)和73.9%(17/23),优于对照组的38.1%(8/21)和66.7%(14/21),但差异无统计学意义(P>0.05)。治疗组KPS评分好转率明显优于对照组,差异有统计学意义(P<0.05)。2组不良反应以1~2级为主,主要有骨髓抑制、消化道反应及局部疼痛。3~4级不良反应少见,治疗组乏力和周围神经毒性明显优于对照组(P<0.05)。结论甘露聚糖肽联合化疗药物治疗恶性浆膜腔积液有一定疗效,能明显改善肿瘤患者的生活质量,不良反应轻,值得临床广泛应用。
目的:評價甘露聚糖肽聯閤化療藥物(順鉑和氟尿嘧啶)灌註治療噁性漿膜腔積液的臨床療效及毒副反應。方法44例噁性漿膜腔積液患者隨機分為2組,所有患者均經漿膜腔穿刺置管,充分引流積液後行灌註治療,治療組(n=23),灌註甘露聚糖肽40~50 mg,順鉑40~60 mg或者氟尿嘧啶0.5~1.0 g;對照組(n=21),灌註順鉑40~60 mg或者氟尿嘧啶0.5~1.0 g。48 h後開放引流管,保持引流通暢,每週1次,連用2週。結果治療組有效率(RR)和疾病控製率(DCR)分彆為47.8%(11/23)和73.9%(17/23),優于對照組的38.1%(8/21)和66.7%(14/21),但差異無統計學意義(P>0.05)。治療組KPS評分好轉率明顯優于對照組,差異有統計學意義(P<0.05)。2組不良反應以1~2級為主,主要有骨髓抑製、消化道反應及跼部疼痛。3~4級不良反應少見,治療組乏力和週圍神經毒性明顯優于對照組(P<0.05)。結論甘露聚糖肽聯閤化療藥物治療噁性漿膜腔積液有一定療效,能明顯改善腫瘤患者的生活質量,不良反應輕,值得臨床廣汎應用。
목적:평개감로취당태연합화료약물(순박화불뇨밀정)관주치료악성장막강적액적림상료효급독부반응。방법44례악성장막강적액환자수궤분위2조,소유환자균경장막강천자치관,충분인류적액후행관주치료,치료조(n=23),관주감로취당태40~50 mg,순박40~60 mg혹자불뇨밀정0.5~1.0 g;대조조(n=21),관주순박40~60 mg혹자불뇨밀정0.5~1.0 g。48 h후개방인류관,보지인류통창,매주1차,련용2주。결과치료조유효솔(RR)화질병공제솔(DCR)분별위47.8%(11/23)화73.9%(17/23),우우대조조적38.1%(8/21)화66.7%(14/21),단차이무통계학의의(P>0.05)。치료조KPS평분호전솔명현우우대조조,차이유통계학의의(P<0.05)。2조불량반응이1~2급위주,주요유골수억제、소화도반응급국부동통。3~4급불량반응소견,치료조핍력화주위신경독성명현우우대조조(P<0.05)。결론감로취당태연합화료약물치료악성장막강적액유일정료효,능명현개선종류환자적생활질량,불량반응경,치득림상엄범응용。
Objective To evaluate the clinical effi cacy and adverse reactions of perfusion with mannatide plus cytotoxic drugs (cisplatin and fluorouracil) in treatment of malignant effusion.Methods 44 patients with malignant effusion were randomly divided into two groups. All patients underwent serous cavity puncturation, continuously draining the effusion via central venous catheter. Then 23 cases in treatment group were treated with mannatide (40~50 mg) plus cisplatin (40~60 mg) orfl uorouracil (0.5~1.0 g) through the central venous catheter; 21 cases in control group only received cisplatin (40~60 mg) orfl uorouracil (0.5~1.0 g). The treatment for two groups was repeated once per week and continued for 2 weeks.Results The response rate and the disease control rate of the treatment group were 47.8% (11/23) and 73.9% (17/23), better than 38.1% (8/21) and 66.7% (14/21) of the control group, but there was no signifi cant statistic difference between the two groups (P>0.05). Life quality improvement rate of the treatment group was still better than the control group (P<0.05). The main side effect of two groups were myelosuppression, gastrointestinal reaction and regional pain.Conclusion Perfusion of mannatide plus cytotoxic drugs to treat malignant effusion is a certain effective and hypotoxic therapy, and can also improve the life quality of patients.